Company News
Iterum Therapeutics reports expanding market access for ORLYNVAHâ„¢, securing nearly 25% insurance coverage in the U.S. and signing a Medicare Part D rebate agreement with a top Pharmacy Benefit Manager, with potential coverage starting in Q1 2026.
Iterum Therapeutics will release its third quarter 2025 financial results on November 14, 2025, with a conference call to discuss results and provide a business update. The company has received FDA approval for ORLYNVAH, an oral antibiotic for treating urinary tract infections.
Iterum Therapeutics reported a Q2 2025 loss of $0.13 per share, higher than expected, as the company prepares for the commercial launch of its oral antibiotic ORLYNVAHâ„¢ for urinary tract infections. The company has secured manufacturing agreements and extended its cash runway into 2026.
Iterum Therapeutics plans to launch ORLYNVAHâ„¢, its first branded antibiotic for uncomplicated urinary tract infections, in August 2025. The company has partnered with EVERSANA for commercialization and has sufficient cash runway into 2026.
Iterum Therapeutics announced a partnership with EVERSANA to commercialize its approved product ORLYNVAHTM, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections, in the U.S. by Q4 2025.
